Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops aim to boost blood flow in glaucoma suspects

NCT ID NCT04401982

Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study compares two eye drop treatments—latanoprost alone versus a combination of netarsudil and latanoprost (Rocklatan)—to see if the combination improves blood flow in the veins around the eye. Researchers will use special imaging techniques to measure blood flow in adults with ocular hypertension or suspected glaucoma. The goal is to understand whether adding netarsudil can increase blood flow beyond what latanoprost does alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rocklatan (netarsudil/latanoprost) and latanoprost
What this could lead to
If successful, this could show that netarsudil improves eye blood flow, potentially leading to better treatments for glaucoma.
What could go wrong
This is a small, early-phase study focused on measuring blood flow, not on long-term outcomes. The results may not translate to better vision or disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Patients are at least 18 years of age. * Patients must have ocular hypertension or be a glaucoma suspect. * Patient must not have used any IOP-lowering medication (topical or systemic) within the past 6 months * Patients must have open angles on gonioscopy. * All patients will have at least one recorded visual field examination within 6 months of enrollment in the study. Visual fields will be assessed using the Hodapp-Andersen-Parish criteria. Exclusion: * Participation in other investigational studies, unless such participation does not involve the administration of any drugs or agents that could impact the results of this study or have an effect on episcleral flow, as determined by the Investigator. * Prior intraocular surgery other than uncomplicated cataract surgery. * Allergy or history of adverse reaction to ICG, shellfish, or Iodine. * Significant liver disease or uremia. * Secondary glaucoma including exfoliation glaucoma, pigmentary glaucoma, or history of acute angle closure. * Moderate or severe visual field deficits as per Hodapp-Anderson-Parish criteria. * Any condition precluding imaging including reliable visual fields, disc photography, or use of study treatments including media opacity or tilted optic disk * Pregnant or nursing patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ocular hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ocular hypertension Suspect glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    4 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Maryland Eye Consultants and Surgeons

    RECRUITING

    Silver Spring, Maryland, 20902, United States

  • UM Faculty Physicians, Inc. | 5900 Waterloo Crossing

    RECRUITING

    Columbia, Maryland, 21045, United States

  • University Physicians Inc.

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact Email: •••••@•••••

  • University of Maryland Medical Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.